
1. aids res hum retroviruses. 2000 jan 20;16(2):91-8.

recombinant bacillus calmette-guérin potential vector preventive hiv
type 1 vaccines.

falk la(1), goldenthal kl, esparza j, aguado mt, osmanov s, ballou wr, beddows s,
bhamarapravati n, biberfeld g, ferrari g, hoft d, honda m, jackson a, lu y,
marchal g, mckinney j, yamazaki s.

author information: 
(1)u.s. food drug administration, center biologics evaluation and
research, office vaccines research review, rockville, maryland 20852-1448,
usa.

in august 1997, world health organization (who) joint united nations 
programme hiv/aids (unaids) convened expert working group discuss
current strategies development hiv type 1 vaccines. based the
recent findings investigators japan's national institute infectious
diseases (niid) tokyo using recombinant bacillus calmette-guérin (rbcg) a
potential vectored vaccine hiv, recommendation made work
in area priority. result, working group reconvened in
september 1998 discuss progress date vaccine approach, as
well areas related research assess feasibility bcg-vectored hiv
vaccine. report summarizes discussions addressing available
scientific data potential use rbcg vector preventive hiv
vaccines, work necessary move candidate vaccines phase 1
clinical trials, recommendations targeted facilitating long-term
development rbcg-vectored hiv vaccines.

doi: 10.1089/088922200309421 
pmid: 10659047  [indexed medline]

